


BREAST CANCER SCREENING AND DIAGNOSIS


VARIATION IN GENETIC TESTING RATES AMONG BREAST CANCER PATIENTS AT DIAGNOSIS



Genetic Testing Rates (e.g., BRCA1/2) at Initial Breast Cancer Diagnosis (n=173)

There is wide variability in the use of genetic testing at initial breast cancer diagnosis, suggesting potential opportunities to better understand and support testing practices across different settings.


GENETIC RE-TESTING AT METASTATIC DIAGNOSIS IS INFREQUENTLY PERFORMED



Percentage of Breast Cancer Patients Undergoing Genetic Re-Testing at Metastatic Diagnosis (n=173)

Genetic re-testing at the time of metastatic breast cancer diagnosis appears to be underutilized, with nearly half of oncologists re-testing very few patients, pointing to an opportunity to understand better when and why re-testing is pursued.

TESTING HER2 ULTRA-LOW NOT YET STANDARDIZED ACROSS PRACTICES



The mixed adoption of ultra-low HER2 testing suggests growing awareness but varied implementation, with many practices either using it selectively or planning to adopt it, and a notable portion of respondents still unaware of its availability or role in breast cancer diagnostics.